Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer

Peter Kirkbride, Mathew Hatton, Paul Lorigan, Patrick Joyce, Patricia Fisher

    Research output: Contribution to journalArticlepeer-review

    Abstract

    In an attempt to evaluate the safety and efficacy of chemotherapy and continuous hyperfractionated radiotherapy (CHART) for non small cell lung cancer (NSCLC), a dose-escalation study was initiated, in which patients were treated with a combination of Vinorelbine and Carboplatin chemotherapy and CHART radiotherapy. The first cohort of 3 patients were treated with induction chemotherapy (Vinorelbine 30mg/m2 weeks 1,2,4 and 5, and Carboplatin, AUC = 5mg/ml/min weeks 1 and 4) followed by CHART radiotherapy (5400cGy in 36 fractions in 12 days on weeks 7 and 8). It was intended to then treat subsequent cohorts of patients with increasing doses of chemotherapy concomitantly with CHART, but unfortunately 2 of the first 3 patients both developed respiratory failure due to widespread pulmonary fibrosis, and died 7 and 9 weeks after completing treatment. At this point the study was closed. The combination of chemotherapy and CHART for NSCLC may have significant pulmonary toxicity and this potentially serious adverse effect needs to be carefully considered when planning future research studies is this area. © 2002 The Royal College of Radiologists. Published by Elsevier Science Ltd. All rights reserved.
    Original languageEnglish
    Pages (from-to)361-366
    Number of pages5
    JournalClinical Oncology
    Volume14
    Issue number5
    DOIs
    Publication statusPublished - Oct 2002

    Keywords

    • CHART
    • Chemotherapy
    • Non-small cell lung cancer
    • Pulmonary fibrosis
    • Radiotherapy

    Fingerprint

    Dive into the research topics of 'Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer'. Together they form a unique fingerprint.

    Cite this